{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Locally+Advanced+%2F+Metastatic+Solid+Tumors&page=4",
    "query": {
      "condition": "Locally Advanced / Metastatic Solid Tumors",
      "page": 4
    },
    "page_size": 10
  },
  "pagination": {
    "page": 4,
    "page_size": 10,
    "total_count": 431,
    "total_pages": 44,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Locally+Advanced+%2F+Metastatic+Solid+Tumors&page=5&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Locally+Advanced+%2F+Metastatic+Solid+Tumors&page=3&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-03T03:41:43.577Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02751528",
      "title": "QUILT-3.013: Study of Ad5 [E1-, E2b-]-HER2/Neu Vaccine (ETBX-021) in Subjects With Unresectable Locally Advanced or Metastatic HER2-Expressing Breast Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cancer"
      ],
      "interventions": [
        {
          "name": "ETBX-021",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "NantBioScience, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 3,
      "start_date": "2017-03-04",
      "completion_date": "2018-08-16",
      "has_results": true,
      "last_update_posted_date": "2025-01-13",
      "last_synced_at": "2026-10-03T03:41:43.577Z",
      "location_count": 2,
      "location_summary": "El Segundo, California • Sioux Falls, South Dakota",
      "locations": [
        {
          "city": "El Segundo",
          "state": "California"
        },
        {
          "city": "Sioux Falls",
          "state": "South Dakota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02751528"
    },
    {
      "nct_id": "NCT05862324",
      "title": "TAC T-cells for the Treatment of Claudin 18.2 Positive Solid Tumors (TACTIC-3)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Solid Tumor"
      ],
      "interventions": [
        {
          "name": "TAC01-CLDN18.2",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Triumvira Immunologics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 113,
      "start_date": "2023-08-23",
      "completion_date": "2027-08-01",
      "has_results": false,
      "last_update_posted_date": "2025-02-14",
      "last_synced_at": "2026-10-03T03:41:43.577Z",
      "location_count": 7,
      "location_summary": "Los Angeles, California • San Diego, California • Miami, Florida + 4 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05862324"
    },
    {
      "nct_id": "NCT03295942",
      "title": "A Study of OMP-336B11 in Subjects With Locally Advanced or Metastatic Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Locally Advanced Malignant Neoplasm",
        "Metastatic Cancer"
      ],
      "interventions": [
        {
          "name": "OMP-336B11",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "OncoMed Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "21 Years and older"
      },
      "enrollment_count": 24,
      "start_date": "2017-09-12",
      "completion_date": "2019-07-04",
      "has_results": false,
      "last_update_posted_date": "2020-08-11",
      "last_synced_at": "2026-10-03T03:41:43.577Z",
      "location_count": 1,
      "location_summary": "San Antonio, Texas",
      "locations": [
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03295942"
    },
    {
      "nct_id": "NCT07454642",
      "title": "AVA6103 in Subjects With Locally Advanced or Metastatic Selected Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Vulvar Adenocarcinoma",
        "PDAC - Pancreatic Ductal Adenocarcinoma",
        "Gastric Adenocarcinoma",
        "GEJ Adenocarcinoma",
        "Cervical Adenocarcinoma",
        "Cervical Adenosquamous Carcinoma",
        "Small Cell Carcinoma of Lung",
        "Colorectal Cancer",
        "Hormone Receptor Positive Breast Carcinoma"
      ],
      "interventions": [
        {
          "name": "AVA6103",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Avacta Life Sciences Ltd",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 174,
      "start_date": "2026-03-31",
      "completion_date": "2030-06",
      "has_results": false,
      "last_update_posted_date": "2026-06-02",
      "last_synced_at": "2026-10-03T03:41:43.577Z",
      "location_count": 3,
      "location_summary": "Grand Rapids, Michigan • Irving, Texas • Fairfax, Virginia",
      "locations": [
        {
          "city": "Grand Rapids",
          "state": "Michigan"
        },
        {
          "city": "Irving",
          "state": "Texas"
        },
        {
          "city": "Fairfax",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07454642"
    },
    {
      "nct_id": "NCT03746431",
      "title": "A Phase 1 Study of [225Ac]-FPI-1434 Injection",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Solid Tumours",
        "Endometrial Cancer",
        "Cervical Cancer",
        "Ovarian Cancer",
        "Breast Cancer",
        "Triple Negative Breast Cancer (TNBC)",
        "HER2-negative Breast Cancer",
        "Head and Neck Squamous Cell Carcinoma (HNSCC)",
        "Adrenocortical Carcinoma",
        "Uveal Melanoma"
      ],
      "interventions": [
        {
          "name": "[111In]-FPI-1547 Injection",
          "type": "DRUG"
        },
        {
          "name": "[225Ac]-FPI-1434 Injection multi-dose",
          "type": "DRUG"
        },
        {
          "name": "FPI-1175 Infusion",
          "type": "BIOLOGICAL"
        },
        {
          "name": "[225Ac]-FPI-1434 Injection single-dose",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Fusion Pharmaceuticals Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 78,
      "start_date": "2019-01-17",
      "completion_date": "2025-12-03",
      "has_results": false,
      "last_update_posted_date": "2026-01-07",
      "last_synced_at": "2026-10-03T03:41:43.577Z",
      "location_count": 7,
      "location_summary": "Duarte, California • Boston, Massachusetts • Minneapolis, Minnesota + 4 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "Buffalo",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03746431"
    },
    {
      "nct_id": "NCT06960395",
      "title": "Safety and Preliminary Efficacy of VIR-5525 and VIR-5525 + Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Solid Tumor Malignancies",
        "EGFR Positive Solid Tumors",
        "EGFR"
      ],
      "interventions": [
        {
          "name": "VIR-5525",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Vir Biotechnology, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 450,
      "start_date": "2025-07-22",
      "completion_date": "2029-08",
      "has_results": false,
      "last_update_posted_date": "2026-04-13",
      "last_synced_at": "2026-10-03T03:41:43.577Z",
      "location_count": 2,
      "location_summary": "Scottsdale, Arizona • Houston, Texas",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06960395"
    },
    {
      "nct_id": "NCT06548672",
      "title": "A Study to Assess the Safety, Pharmacokinetics, and Antitumor Activity of BC3195 in Patients With Advanced or Metastatic Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Cancer",
        "Metastatic Solid Tumor"
      ],
      "interventions": [
        {
          "name": "BC3195",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Biocity Biopharmaceutics Co., Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 148,
      "start_date": "2024-06-24",
      "completion_date": "2027-06-30",
      "has_results": false,
      "last_update_posted_date": "2024-08-12",
      "last_synced_at": "2026-10-03T03:41:43.577Z",
      "location_count": 1,
      "location_summary": "Cleveland, Ohio",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06548672"
    },
    {
      "nct_id": "NCT02610075",
      "title": "Phase Ib Study to Determine MTD of AZD1775 Monotherapy in Patients With Locally Advanced or Metastatic Solid Tumours.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Locally Advanced Solid Tumours",
        "Metastatic Solid Tumours",
        "Ovarian Cancer"
      ],
      "interventions": [
        {
          "name": "AZD1775",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "130 Years",
        "sex": "ALL",
        "summary": "18 Years to 130 Years"
      },
      "enrollment_count": 62,
      "start_date": "2015-12-01",
      "completion_date": "2018-04-26",
      "has_results": false,
      "last_update_posted_date": "2023-07-03",
      "last_synced_at": "2026-10-03T03:41:43.577Z",
      "location_count": 3,
      "location_summary": "Scottsdale, Arizona • Denver, Colorado • Nashville, Tennessee",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02610075"
    },
    {
      "nct_id": "NCT04094610",
      "title": "A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Locally Advanced Solid Tumors",
        "Metastatic Solid Tumors",
        "Lymphoma",
        "Primary CNS Tumors"
      ],
      "interventions": [
        {
          "name": "Oral repotrectinib (TPX-0005)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Turning Point Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "25 Years",
        "sex": "ALL",
        "summary": "Up to 25 Years"
      },
      "enrollment_count": 75,
      "start_date": "2020-03-12",
      "completion_date": "2027-09-30",
      "has_results": false,
      "last_update_posted_date": "2026-09-25",
      "last_synced_at": "2026-10-03T03:41:43.577Z",
      "location_count": 20,
      "location_summary": "Los Angeles, California • Aurora, Colorado • Orlando, Florida + 14 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04094610"
    },
    {
      "nct_id": "NCT02001623",
      "title": "Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Ovary Cancer",
        "Cervix Cancer",
        "Endometrium Cancer",
        "Bladder Cancer",
        "Prostate Cancer (CRPC)",
        "Esophagus Cancer",
        "Lung Cancer(NSCLC)",
        "Squamous Cell Carcinoma of the Head and Neck (SCCHN)"
      ],
      "interventions": [
        {
          "name": "Tisotumab Vedotin (HuMax-TF-ADC)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Seagen Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 195,
      "start_date": "2013-11-30",
      "completion_date": "2019-05-02",
      "has_results": true,
      "last_update_posted_date": "2021-12-29",
      "last_synced_at": "2026-10-03T03:41:43.577Z",
      "location_count": 8,
      "location_summary": "Orange, California • New Haven, Connecticut • Miami, Florida + 5 more",
      "locations": [
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Las Vegas",
          "state": "Nevada"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02001623"
    }
  ]
}